9th Feb 2016 11:26
LONDON (Alliance News) - NetScientific PLC said Tuesday one of its portfolio companies, PDS Biotechnology, has inked a cooperative research and development agreement with the National Cancer Institute.
This is a division of the US government's National Institutes of Health.
Under the agreement the two aim to co-develop novel cancer immunotherapies through phase II clinical trials that will start in 2016 and 2017.
"Securing a cooperative research and development agreement with the leading cancer research institute in the US is a landmark moment for PDS Biotechnology and a huge endorsement of its technology," said Chief Executive Officer Francois Martelet in a statement.
Shares in NetScientific were down 1.2% at 85.00 pence Tuesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific